Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T16:04:23.178Z.
Calculation as of: 2026-10-06T16:04:23.178Z.
Quote observation: 2026-10-06T15:58:50.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0697fbf5b2c9a172e1581fe1039fb6f1f0c6a9f8a555274951ccff759adaa9ee
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$3.38M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.23M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Nexalin Technology, Inc. (NXL) | $3.55M | N/A | N/A | N/A | N/A |
| Mustang Bio, Inc. (MBIO)vs › | $3.49M | N/A | 0.09% | 0.09% | 0.09% |
| Eocene Ltd. (EOCN)vs › | $3.48M | N/A | N/A | N/A | N/A |
| Evogene Ltd. (EVGN)vs › | $3.41M | N/A | N/A | N/A | N/A |
| Moolec Science S.A. (MLEC)vs › | $3.39M | N/A | N/A | N/A | N/A |
| Cadrenal Therapeutics, Inc. Common Stock (CVKD)vs › | $3.38M | N/A | N/A | N/A | N/A |
| Aethlon Medical, Inc. (AEMD)vs › | $3.29M | N/A | N/A | N/A | N/A |
| Paranovus Entertainment Technology Ltd. (PAVS)vs › | $3.23M | N/A | N/A | N/A | N/A |
| MBody AI Ltd. (MBAI)vs › | $3.17M | N/A | N/A | N/A | N/A |
| IceCure Medical Ltd (ICCM)vs › | $3.11M | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
